Table 4.

Sensitivity and specificity of ICOS+ CD4 T cells as a pharmacodynamic biomarker of anti-CTLA-4 therapy

NMore than 5.63a (+)Sensitivity (95% CI)Specificity (95% CI)
PretreatmentAll samples56296.4% (87.7–99.6)
After dose 2 of ipilimumabPatients with cancer352571% (53.7–85.4)
  • aUpper bound of 95% CI from baseline samples.